Professor Andreas Baumbach

Profile

Professor Andreas Baumbach is active in coronary and structural intervention, and has published extensively in the field of interventional research covering preclinical, first in man, pivotal and post market studies. He has an interest in device innovation and regulatory pathways.

Professor Baumbach has a strong commitment to training and education. He is on the board of directors of the largest interventional congress EuroPCR and PCR London Valves. He is past President of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Research

Group members

Prof Christos Bourantas, Dr Anantharam Ramasary, Dr Nida Ahmed, Dr Ratesh Bajaj, Dr Kush Patel

Summary

Active in first in human trials, as well as large scale multinational, multi-centre randomised clinical trial evaluation of novel devices.

Publications

• Ramasamy A, Sivananthan A, Tanboga IH et al. (2026). Efficacy of the Shear Stress Pattern Computed in Coronary Artery Reconstruction Models With and Without Side Branches in Predicting Plaque Progression.. nameOfConference

  
  

  DOI: 10.1161/atvbaha.126.324466

  
  

  QMRO: qmroHref
• Buszman PP, Granada JF, Amabile N et al. (publicationYear). Comprehensive and Contemporary Pre-clinical Evaluation of Novel Transcatheter Aortic Valves. A Scientific Statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, the ESC Working Group on Cellular Biology of the Heart, and the ESC Working Group on Cardiovascular Surgery. nameOfConference

  
  

  DOI: 10.1093/ehjvshd/xwag039

  
  

  QMRO: qmroHref
• Tobe A, van Royen N, Amat-Santos IJ et al. (2026). Win ratio analysis for the 1-year composite endpoint: a substudy of the LANDMARK trial. nameOfConference

  
  

  DOI: 10.1093/ehjvshd/xwag038

  
  

  QMRO: qmroHref
• Tobe A, Smits PC, van Royen N et al. (2026). Pacemaker recovery after permanent pacemaker implantation post-transcatheter aortic valve implantation: A sub-study of the LANDMARK trial. nameOfConference

  
  

  DOI: 10.1016/j.ijcard.2026.134525

  
  

  QMRO: qmroHref
• Popolo Rubbio A, Sisinni A, Criscione E et al. (2026). Supra-Annular Versus Intra-Annular Devices for Transcatheter Aortic Valve-in-Valve Replacement: The PANDORA International Registry.. nameOfConference

  
  

  DOI: 10.1161/jaha.125.046180

  
  

  QMRO: qmroHref
• Tsai T, Wykrzykowska J, Sharif F et al. (2026). 6 to 12-month vs. 1-month dual antiplatelet therapy: comparative outcomes after aspirin cessation with HT supreme stent in the pooled PIONEER III and PIONEER IV trial analysis. nameOfConference

  
  

  DOI: 10.1093/eurheartjsupp/suag056.037

  
  

  QMRO: qmroHref
• Onuma Y, Tobe A, Gallazzi M et al. (2026). Cardiac damage and 1-year clinical outcomes after transcatheter aortic valve implantation: substudy of the LANDMARK trial. nameOfConference

  
  

  DOI: 10.1093/eurheartjsupp/suag056.070

  
  

  QMRO: qmroHref
• Tobe A, Onuma Y, Van Royen N et al. (2026). Comprehensive assessment of 1-year echocardiograms after transcatheter aortic valve implantation: insights from the LANDMARK trial. nameOfConference

  
  

  DOI: 10.1093/eurheartjsupp/suag056.072

  
  

  QMRO: qmroHref
• Tobe A, Smits P, Van Royen N et al. (2026). Conduction disturbance recovery after permanent pacemaker implantation post-transcatheter aortic valve implantation: substudy of the LANDMARK trial. nameOfConference

  
  

  DOI: 10.1093/eurheartjsupp/suag056.068

  
  

  QMRO: qmroHref
• Tobe A, Van Royen N, Amat-Santos I et al. (2026). Win ratio analysis of 1-year outcomes after transcatheter aortic valve implantation: substudy of the LANDMARK trial. nameOfConference

  
  

  DOI: 10.1093/eurheartjsupp/suag056.069

  
  

  QMRO: qmroHref

Collaborators

External

• Meril Life
• Jenavalve
• Microport

Disclosures

• Institutional Research Support: Abbott Vascular
• Consultation and Speaker Fees: Astra Zeneca, Sinomed, Microport, Medtronic, Faraday Pi-Cardia, Biosensors, Jenavalve